ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,070.55
      1.20%
      US Tech 100
      17,118.40
      0.68%
      Dow Jones
      38,503.69
      0.69%
      Brent Oil
      87.635
      0.08%
      Bitcoin
      66,587.70
      0.27%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Galmed Pharmaceuticals Ltd (GLMD)

      7. Galmed Pharmaceuticals Ltd (GLMD) News

      GLMD

      Galmed Pharmaceuticals (GLMD)

      Galmed Pharmaceuticals Ltd
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:GLMD
      DateTimeSourceHeadlineSymbolCompany
      04/04/20245:06PMPR Newswire (US)Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023NASDAQ:GLMDGalmed Pharmaceuticals Ltd
      03/15/20249:00AMPR Newswire (US)Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver FibrosisNASDAQ:GLMDGalmed Pharmaceuticals Ltd
      02/14/20242:14PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
      02/12/20244:15PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
      11/30/202312:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:GLMDGalmed Pharmaceuticals Ltd
      11/22/20234:48PMEdgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:GLMDGalmed Pharmaceuticals Ltd
      11/20/20234:37PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
      11/20/20234:32PMPR Newswire (US)Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a StudyNASDAQ:GLMDGalmed Pharmaceuticals Ltd
      11/01/20234:15PMEdgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:GLMDGalmed Pharmaceuticals Ltd
      09/26/20238:51AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
      09/26/20238:30AMPR Newswire (US)Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal FibrosisNASDAQ:GLMDGalmed Pharmaceuticals Ltd
      09/22/20234:15PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
      09/22/20234:05PMPR Newswire (US)Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price NotificationNASDAQ:GLMDGalmed Pharmaceuticals Ltd
      09/21/20237:30AMEdgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
      09/20/20234:30PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
      09/13/20234:01PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
      08/09/20234:43PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
      08/09/20234:30PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
      08/02/20234:30PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
      07/21/202310:12AMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:GLMDGalmed Pharmaceuticals Ltd
      07/18/20239:25AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
      07/18/20239:23AMEdgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
      07/14/20239:44AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
      07/14/20239:30AMPR Newswire (US)Galmed Pharmaceuticals Announces Pricing of $7 Million Public OfferingNASDAQ:GLMDGalmed Pharmaceuticals Ltd
      07/13/20235:08PMEdgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
      07/12/20235:29PMEdgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
      07/10/20238:10AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
      07/10/20238:10AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
      07/10/20238:00AMPR Newswire (US)Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSCNASDAQ:GLMDGalmed Pharmaceuticals Ltd
      06/28/20238:41AMEdgar (US Regulatory)Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)NASDAQ:GLMDGalmed Pharmaceuticals Ltd
       Showing the most relevant articles for your search:NASDAQ:GLMD